Outset Medical Inc (OM)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $70.39M
Last updated: Nov 17, 2026 at 11:05 AM ET
Outset Medical Inc (OM) Earnings: Report Dates and Results
Outset Medical (OM) is expected to report earnings on Jan 11, 2027. In the quarter ended Sep 30, 2026, Outset Medical reported EPS of -$0.77, above the -$0.84 estimate. It beat the EPS estimate in 3 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
OM has an expected report date of Jan 11, 2027.
OM Earnings Call
The latest OM earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 26 quarters below that had an estimate, OM beat 12 and missed 14. Revenue for the quarter ended Sep 30, 2026 was $33.60M, up 14.2% from $29.43M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.77 | -$0.84 | N/A | +8.33% | Beat | N/A | 3 | 1 up, 0 down | Nov 4, 2026 | $33.60M |
| Jun 30, 2026 | -$0.94 | -$0.88 | N/A | -6.82% | Miss | N/A | 3 | 2 up, 0 down | Aug 6, 2026 | $31.64M |
| Mar 31, 2026 | -$0.83 | -$0.79 | -$0.83 - -$0.75 | -5.06% | Miss | N/A | 3 | 0 up, 3 down | May 7, 2026 | $27.86M |
| Dec 31, 2025 | -$0.84 | -$0.67 | -$0.85 - -$0.45 | -25.37% | Miss | N/A | 4 | 1 up, 2 down | Feb 11, 2026 | $28.87M |
| Sep 30, 2025 | -$0.69 | -$0.65 | -$0.70 - -$0.62 | -6.15% | Miss | N/A | 4 | 1 up, 3 down | Nov 10, 2025 | $29.43M |
| Jun 30, 2025 | -$0.84 | -$0.98 | -$1.76 - -$0.64 | +14.29% | Beat | N/A | 4 | 3 up, 1 down | Aug 6, 2025 | $31.42M |
| Mar 31, 2025 | -$3.24 | -$0.94 | -$1.45 - -$0.31 | -244.68% | Miss | N/A | 4 | 4 up, 0 down | May 7, 2025 | $29.75M |
| Dec 31, 2024 | -$5.55 | -$6.19 | -$6.45 - -$6.00 | +10.34% | Beat | N/A | 4 | 1 up, 2 down | Feb 19, 2025 | $29.47M |
| Sep 30, 2024 | -$5.85 | -$6.32 | -$6.90 - -$5.55 | +7.44% | Beat | N/A | 6 | 0 up, 0 down | Nov 6, 2024 | $28.67M |
| Jun 30, 2024 | -$7.05 | -$6.79 | -$7.80 - -$3.75 | -3.83% | Miss | N/A | 6 | 0 up, 0 down | Aug 7, 2024 | $27.39M |
| Mar 31, 2024 | -$8.55 | -$8.23 | -$9.30 - -$6.60 | -3.89% | Miss | N/A | 7 | 0 up, 0 down | May 8, 2024 | $28.17M |
| Dec 31, 2023 | -$8.85 | -$9.22 | -$9.90 - -$8.25 | +4.01% | Beat | N/A | 6 | 0 up, 0 down | Feb 21, 2024 | $30.51M |
| Sep 30, 2023 | -$10.65 | -$10.00 | -$10.79 - -$8.55 | -6.50% | Miss | N/A | 6 | 5 up, 1 down | Nov 7, 2023 | $30.36M |
| Jun 30, 2023 | -$10.35 | -$10.89 | -$13.49 - -$10.64 | +4.96% | Beat | N/A | 3 | 0 up, 0 down | Aug 2, 2023 | $36.04M |
| Mar 31, 2023 | -$10.80 | -$10.35 | -$14.09 - -$9.75 | -4.35% | Miss | N/A | 5 | 0 up, 0 down | May 3, 2023 | $33.47M |
| Dec 31, 2022 | -$10.65 | -$11.19 | -$14.84 - -$11.09 | +4.83% | Beat | N/A | 4 | 0 up, 0 down | Feb 13, 2023 | $32.01M |
| Sep 30, 2022 | -$10.50 | -$10.57 | -$13.64 - -$10.04 | +0.66% | Beat | N/A | 5 | 0 up, 0 down | Nov 8, 2022 | $27.76M |
| Jun 30, 2022 | -$11.55 | -$8.93 | N/A | -29.34% | Miss | N/A | 5 | 1 up, 0 down | Aug 1, 2022 | $25.06M |
| Mar 31, 2022 | -$10.05 | -$9.93 | -$11.84 - -$8.70 | -1.21% | Miss | N/A | 5 | 2 up, 0 down | May 4, 2022 | $30.55M |
| Dec 31, 2021 | -$11.55 | -$10.01 | N/A | -15.38% | Miss | N/A | 4 | 0 up, 0 down | Feb 16, 2022 | $28.15M |
| Sep 30, 2021 | -$8.85 | -$10.29 | -$12.74 - -$8.85 | +13.99% | Beat | N/A | 5 | 5 up, 0 down | Nov 3, 2021 | $26.32M |
| Jun 30, 2021 | -$8.55 | -$10.08 | -$11.39 - -$9.15 | +15.18% | Beat | N/A | 5 | N/A | Aug 5, 2021 | $25.22M |
| Mar 31, 2021 | -$8.40 | -$12.05 | -$14.24 - -$10.04 | +30.29% | Beat | N/A | 6 | N/A | May 5, 2021 | $22.92M |
| Dec 31, 2020 | -$0.75 | -$0.66 | -$0.74 - -$0.60 | -13.64% | Miss | N/A | 5 | N/A | Mar 9, 2021 | $17.25M |
| Sep 30, 2020 | -$32.71 | -$27.37 | -$62.07 - -$16.64 | -19.51% | Miss | N/A | 3 | N/A | Nov 11, 2020 | $13.76M |
| Jun 30, 2020 | -$0.50 | -$2.58 | N/A | +80.62% | Beat | N/A | N/A | N/A | Sep 16, 2020 | $11.74M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$5.61, after -$27.00 the year before. It was -$33.96 for the year ended Dec 31, 2020, the oldest of the 6 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$5.61 | N/A |
| Dec 31, 2024 | -$27.00 | N/A |
| Dec 31, 2023 | -$40.65 | N/A |
| Dec 31, 2022 | -$42.75 | N/A |
| Dec 31, 2021 | -$37.35 | N/A |
| Dec 31, 2020 | -$33.96 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 3,600 words across 6 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 3,624 | 6 | |
| 2026Q2 | Jun 30, 2026 | 3,491 | 6 | |
| 2026Q1 | Mar 31, 2026 | 3,832 | 7 | |
| 2025Q4 | Dec 31, 2025 | 5,184 | 8 | |
| 2025Q3 | Sep 30, 2025 | 5,421 | 8 | |
| 2025Q2 | Jun 30, 2025 | 5,136 | 8 | |
| 2025Q1 | Mar 31, 2025 | 5,294 | 7 | |
| 2024Q4 | Dec 31, 2024 | 4,883 | 7 |
2026Q3 Earnings Call
Opening remarks
Tina Jacobson Head of Investor Relations Good afternoon, everyone, and welcome to Outset Medical's Third Quarter 2026 Earnings Call. Today's speakers are Leslie Trigg, Chair and Chief Executive Officer, and Renee Gaeta, Chief Financial Officer. The company issued a news release after the close of the market today, which can be found in the Investors section of outsetmedical.com. This call is being recorded and will be archived there as well. All forward-looking statements made during today's call are intended to be protected under the Private Securities Litigation Reform Act of 1995. Outset assumes no obligation to update these statements. For a list and description of the risks and uncertainties associated with the business, please refer to Outset's public filings with the Securities and Exchange Commission, including its latest annual and quarterly reports. I will now turn the call over to Leslie Trigg.
Leslie Trigg Chair and CEO Good afternoon, everyone, and thank you for joining us. Our team executed well in the third quarter, delivering solid progress against our strategic priorities. Just as importantly, we continue doing the foundational work that is strengthening the business and aligning our teams to drive more predictable, profitable growth. I'm confident that these efforts are positioning Outset to capture the significant opportunity ahead. With that, I'll dive right into third quarter results, beginning with financial performance. Revenue of $33.6 million was up 14% year-over-year and up 6% sequentially. Each of our revenue line items contributed to growth both year-over-year and sequentially. We were particularly encouraged to see console revenue growth of 26% year-over-year, driven by new and refreshed console sales. In terms of recurring revenue, in addition to solid treatment volume, sales of our EMR offering are starting to ramp and grew 23% year-over-year. Ongoing operational initiatives improved non-GAAP gross margin, while expense discipline delivered significant operating expense leverage. Our clinical excellence team was busy again this quarter, with a full lineup of new go-live implementations completed for new customers and existing customers expanding to new locations. Among those were four of the top 10 U.S. health systems. We draw on years of valuable experience to support hospitals as they transition from outsourced to in-house, starting with a detailed project plan customized to each hospital's needs, then executing that plan through nurse training, physician education, and change management support. All of that requires well-oiled cross-functional execution, and our teams continue to deliver time and again. Beyond implementation, our clinical excellence team members collaborate with customers to maximize Tablo's system-wide benefits, helping to identify the outcomes that matter most to each organization. Tablo's unique data ecosystem, now comprising more than 10 trillion data points, enables us to track and trend key performance indicators and regularly share the insights with customers.
Frequently Asked Questions About OM
When is Outset Medical's next earnings date?
Outset Medical's next earnings report is expected for Jan 11, 2027.
Did OM beat earnings estimates last quarter?
Yes. Outset Medical reported EPS of -$0.77 for the quarter ended Sep 30, 2026, above the -$0.84 estimate, a 8.33% surprise.
What EPS do analysts expect from OM next quarter?
The consensus EPS estimate for Outset Medical for the quarter ending Dec 31, 2026 is -$0.68 from 6 analysts, with estimates from -$0.72 to -$0.63.
How often does OM beat earnings estimates?
Outset Medical beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of -31.89%.
OM pages: Overview, Earnings, Forecast, Financials, Competitors